Posts Tagged: Dana-Farber Cancer Institute

Findings from Preclinical Study Presented at American Society of Hematology 2014 Annual Meeting TORONTO AND SAN DIEGO (Dec. 6, 2014) -- Triphase Accelerator Corporation, a private drug development company dedicated to advancing novel compounds through Phase II proof-of-concept clinical studies, today announced preclinical study results demonstrating that the combination of its highly differentiated proteasome inhibitor, marizomib, and pomalidomide (Pomalyst®) was synergistic in killing multiple myeloma cells. MaRS Innovation is an early-stage investor in Triphase. See our web archive for more details. Combined doses of ... Read more